Status:
COMPLETED
Efficacy and Safety for Different Regimen of VTE Pharmacoprophylaxis Among Severely Burn Patients
Lead Sponsor:
King Abdullah International Medical Research Center
Conditions:
Burns
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims to assess the feasibility and safety of VTE prophylaxis for 3 modality regimens (Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hou...
Detailed Description
This is a pilot , randomized control trial-Open label, prospective trial in tertiary academic hospitals for patient admitted to burn ICU for at least 24 hours of injury or transferred from other hospi...
Eligibility Criteria
Inclusion
- Burn ICU admitted adult patients, age ≥ 18 years old.
- Body Mass Index of 18.5 to \< 40 kg/m2.
- TBSA of 20% or more.
Exclusion
- VTE history.
- Death within 24 hours of injury.
- Burn injuries combined with trauma requiring withholding pharmacoprophylaxis more than 48 hours.
- Coagulopathy (INR \> 1.7, PTT\> 2 times upper normal limit, platelet \< 50k mm3)
- Patient with positive baseline US for VTE.
- Heparin induced thrombocytopenia (HIT).
- Active bleeding.
- Patients with CrCl of 30 ml/min or less.
- Patients using anticoagulation treatment dose for other indications.
Key Trial Info
Start Date :
April 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05237726
Start Date
April 5 2020
End Date
February 28 2022
Last Update
December 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Abdulaziz Medical City
Riyadh, Saudi Arabia, 11426